FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial
First approval of a PARP inhibitor in combination with a new hormonal agent in mCRPC
RAHWAY,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Hormones | Prednisolone | Prednisone | Prostate Cancer